NATCO PHARMA LTD. - 524816 - Closure of Trading Window
Closure of Trading Window31-03-2022
NATCO PHARMA LTD. - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for NDL Infra Tech Pvt Ltd29-03-2022
NATCO PHARMA LTD. - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bapanna Alapati29-03-2022
NATCO PHARMA LTD. - 524816 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Natco Pharma Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here28-03-2022
NATCO PHARMA LTD. - 524816 - Results Of Postal Ballot Notice Dated 14Th February, 2022
Results of Postal Ballot Notice dated 14th February, 2022 along with Scrutinizer Report26-03-2022
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
issue of duplicate share certificate23-03-2022
Natco Pharma share price rises 9% on launch of generic of Revlimid in US
The share touched a 52-week high of Rs 1,188.95 and a 52-week low of Rs 750.45 on 24 May, 2021 and 24 February, 2022, respectively.08-03-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO Announces Launch of the First Generic Version of Revlimid(r) (Lenalidomide capsules), in the U.S. market07-03-2022
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
intimation of Loss of share certificate02-03-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
News paper publication of Notice of Postal ballot26-02-2022